Bibliographic Details
| Title: |
Tecovirimat Resistance in Mpox Patients, United States, 2022–2023. |
| Authors: |
Smith, Todd G.1, Gigante, Crystal M.1, Wynn, Nhien T.1, Matheny, Audrey1, Davidson, Whitni1, Yong Yang2, Condori, Rene Edgar1, O’Connell, Kyle1,2, Kovar, Lynsey3, Williams, Tracie L.1, Yu, Yon C.1, Petersen, Brett W.1, Baird, Nicolle1, Lowe, David1, Yu Li1, Satheshkumar, Panayampalli S.1, Hutson, Christina L.1 |
| Source: |
Emerging Infectious Diseases. Dec2023, Vol. 29 Issue 12, p2426-2432. 7p. |
| Abstract: |
During the 2022 multinational outbreak of monkeypox virus (MPXV) infection, the antiviral drug tecovirimat (TPOXX; SIGA Technologies, Inc., https://www.siga. com) was deployed in the United States on a large scale for the first time. The MPXV F13L gene homologue encodes the target of tecovirimat, and single amino acid changes in F13 are known to cause resistance to tecovirimat. Genomic sequencing identified 11 mutations previously reported to cause resistance, along with 13 novel mutations. Resistant phenotype was determined using a viral cytopathic effect assay. We tested 124 isolates from 68 patients; 96 isolates from 46 patients were found to have a resistant phenotype. Most resistant isolates were associated with severely immunocompromised mpox patients on multiple courses of tecovirimat treatment, whereas most isolates identified by routine surveillance of patients not treated with tecovirimat remained sensitive. The frequency of resistant viruses remains relatively low (<1%) compared with the total number of patients treated with tecovirimat. [ABSTRACT FROM AUTHOR] |
|
Copyright of Emerging Infectious Diseases is the property of Centers for Disease Control & Prevention (CDC) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
